智通财经APP讯，泰格医药(03347)公布，公司于2025年11月18日收到持股5%以上股东、董事及总经理 曹晓春女士出具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股 份减持计划期限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司 总股本的0.0406%，占公司A股总股本的0.0475%。 ...

泰格医药（300347）(03347)公布，公司于2025年11月18日收到持股5%以上股东、董事及总经理曹晓春 女士出具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股份减持 计划期限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司总股本 的0.0406%，占公司A股总股本的0.0475%。 ...

HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年11月18日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞 增 玉 先 生；獨 立 非 執 行 董 ...

（编辑 任世碧） 证券日报网讯 11月18日晚间，泰格医药发布公告称，截至2025年11月18日，公司持股5%以上股东、董 事及总经理曹晓春女士本次股份减持计划期限已届满，在减持计划期间，其合计减持347，600股，占当 前剔除回购专户股份数后公司总股本的0.0406%，占公司A股总股本的0.0475%。 ...

Core Insights - The Medical Health R Index (480016) closed at 7508.88 points, down 0.45%, with a trading volume of 17.774 billion yuan and a turnover rate of 0.67% [1] - Among the index constituents, 16 stocks rose while 33 fell, with Bai Li Tian Heng leading the gainers at 2.32% and Tigermed leading the decliners at 3.42% [1] Index Performance - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 92.32, down 1.54%, and a market cap of 275.46 billion yuan - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 61.78, down 0.03%, and a market cap of 410.05 billion yuan - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 206.71, up 0.33%, and a market cap of 250.62 billion yuan - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 134.25, up 0.19%, and a market cap of 110.64 billion yuan - Other notable constituents include Pianzi Shou (sh600436), Yuan Er Fu Ke (sz300015), Kelun Pharmaceutical (sz002422), Xinhecheng (sz002001), Fosun Pharma (sh600196), and Ziji Shenzhou (sh688235) [1] Capital Flow - The Medical Health R Index constituents experienced a net outflow of 2.083 billion yuan from institutional investors, while retail investors saw a net inflow of 1.545 billion yuan [1] - Detailed capital flow for specific stocks shows: - Kelun Pharmaceutical (sz002422) had a net inflow of 23.33 million yuan from institutional investors but a net outflow from retail investors - Tongce Medical (600763) and Yirui Technology (688301) also showed mixed capital flows with varying net inflows and outflows [2]

MACD金叉信号形成，这些股涨势不错！ 格隆汇11月18日丨泰格医药(300347.SZ)公布，公司于2025年11月18日收到董事及总经理曹晓春女士出 具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股份减持计划期 限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司总股本的 0.0406%，占公司A股总股本的0.0475%。 ...

Core Viewpoint - The major shareholder of Tiger Med, Ms. Cao Xiaochun, has completed her share reduction plan, selling a total of 347,600 shares, which represents 0.0406% of the company's total share capital after excluding repurchased shares [1] Summary by Sections - Shareholder Activity - Ms. Cao Xiaochun reduced her holdings by 347,600 shares during the designated reduction period [1] - Following the reduction, she holds 51,314,174 shares, accounting for 6.0007% of the total share capital [1] - Impact on Company Structure - The share reduction did not result in any change in the company's control [1] - The governance structure and ongoing operations of the company remain unaffected [1]

证券代码：300347 证券简称：泰格医药 公告编码（2025）042 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东股份减持计划期限届满暨减持结果的公告 现将其本次股份减持计划的具体实施情况公告如下： 公司持股 5%以上股东曹晓春女士保证向公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、杭州泰格医药科技股份有限公司（以下简称"公司"）于2025年7月28日在巨潮资 讯网披露了《关于持股5%以上股东减持股份的预披露公告》。公司持股5%以上股东、 董事及总经理曹晓春女士计划自上述公告披露之日起15个交易日后3个月内以集中竞价 和/或大宗交易方式减持公司股份不超过3,000,000股（占公告日剔除回购专户股份数后公 司总股本的0.3508%，占公司A股总股本的0.4098%）。 2、公司于2025年11月18日收到曹晓春女士出具的《关于股份减持计划实施完成的告 知函》。截至2025年11月18日，曹晓春女士本次股份减持计划期限已届满，在减持计划期 间，其合计减持347,600股，占当前剔除回购专 ...

Investment Rating - The report continues to recommend the innovative drug and medical device industry chain, indicating a high level of investment interest in this sector [1][5]. Core Views - The report highlights the high prosperity in innovative drugs, suggesting potential value revaluation for companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [2][5]. - It emphasizes the importance of Biopharma/Biotech companies with innovative pipelines and performance entering a volume increase phase, including Innovent Biologics, BeiGene, and others [2][5]. - The report also points out the recovery potential for leading medical equipment companies like United Imaging Healthcare, Lepu Medical, and others [2][5]. Summary by Sections A-Shares Performance - In the second week of November 2025, the A-Shares pharmaceutical sector outperformed, with the SW Pharmaceutical and Biological index rising by 3.3% while the SHCOMP fell by 0.2% [2][30]. - The pharmaceutical commerce, chemical raw materials, and chemical preparations sub-sectors showed strong performance, with increases of 5.7%, 5.1%, and 4.4% respectively [2][30]. - Notable stock gains included GDK (+61.6%), HPGC Renmintongtai Pharmaceutical Corporation (+61.1%), and Chengda Pharmaceuticals Co., Ltd. (+58.3%) [2][30]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also outperformed, with the Hang Seng Healthcare index increasing by 6.8% and the Hong Kong Biotechnology index by 7.1% [2][31]. - In the U.S., the S&P Healthcare Select Sector rose by 3.9%, significantly outperforming the S&P 500, which only increased by 0.1% [2][32]. Valuation Metrics - As of November 14, 2025, the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 77.0% [2][15]. - The report provides earnings forecasts and valuation metrics for various companies, indicating expected growth rates and price-to-earnings ratios for the coming years [6][7].

Market Overview - The medical services sector experienced a decline of 1.69% on November 17, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Baihua Pharmaceutical (600721) saw a significant increase of 8.63%, closing at 10.70, with a trading volume of 792,600 shares and a turnover of 846 million [1] - ST Zhongzhu (600568) rose by 4.80%, closing at 2.40, with a trading volume of 404,900 shares [1] - Meidisi (688202) led the decline with a drop of 5.99%, closing at 62.47, with a trading volume of 36,600 shares and a turnover of 232 million [2] - Kanglong Chemical (300759) and Haoyuan Pharmaceutical (688131) also saw declines of 5.34% and 5.21%, respectively [2] Capital Flow - The medical services sector experienced a net outflow of 1.285 billion from institutional investors, while retail investors saw a net inflow of 993 million [2] - Baihua Pharmaceutical had a net inflow of 71.1 million from institutional investors, but a net outflow of 47.2 million from retail investors [3] - Meidisi had a net outflow of 1.29 million from institutional investors, indicating a shift in investor sentiment [3]